The Effect of Liposome Encapsulation on the Pharmacokinetics of Recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) Therapy after Local Delivery to a Guinea Pig Asthma Model

A. Gibbons; D. Padilla-Carlin; C. Kelly; A.J. Hickey; Clifford Taggart; N.G. McElvaney; S.A. Cryan

doi:10.1007/s11095-011-0454-1

The Effect of Liposome Encapsulation on the Pharmacokinetics of Recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) Therapy after Local Delivery to a Guinea Pig Asthma Model

A. Gibbons
, D. Padilla-Carlin
, C. Kelly
, A.J. Hickey
, Clifford Taggart
, N.G. McElvaney
, S.A. Cryan

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

Inhaled recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) has shown potential for treatment of inflammatory lung conditions. Rapid inactivation of rSLPI by cathepsin L (Cat L) and rapid clearance from the lungs have limited clinical efficacy. Encapsulation of rSLPI within 1,2-Dioleoyl-sn-Glycero-3-[Phospho-L-Serine]:Cholesterol liposomes (DOPS-rSLPI) protects rSLPI against Cat L inactivation in vitro. We aimed to determine the effect of liposomes on rSLPI pharmacokinetics and activity in vitro and after local delivery to the airways in vivo.

Original language	English
Pages (from-to)	2233-2245
Number of pages	13
Journal	Pharmaceutical Research
Volume	28 (9)
Issue number	9
DOIs	https://doi.org/10.1007/s11095-011-0454-1
Publication status	Published - Sept 2011

ASJC Scopus subject areas

Pharmaceutical Science
Organic Chemistry
Molecular Medicine
Pharmacology (medical)
Biotechnology
Pharmacology

Access to Document

10.1007/s11095-011-0454-1

Cite this

Gibbons, A., Padilla-Carlin, D., Kelly, C., Hickey, A. J., Taggart, C., McElvaney, N. G., & Cryan, S. A. (2011). The Effect of Liposome Encapsulation on the Pharmacokinetics of Recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) Therapy after Local Delivery to a Guinea Pig Asthma Model. Pharmaceutical Research, 28 (9)(9), 2233-2245. https://doi.org/10.1007/s11095-011-0454-1

@article{d454e35e6b89471f97d7bb4ed1724016,

title = "The Effect of Liposome Encapsulation on the Pharmacokinetics of Recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) Therapy after Local Delivery to a Guinea Pig Asthma Model",

abstract = "Inhaled recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) has shown potential for treatment of inflammatory lung conditions. Rapid inactivation of rSLPI by cathepsin L (Cat L) and rapid clearance from the lungs have limited clinical efficacy. Encapsulation of rSLPI within 1,2-Dioleoyl-sn-Glycero-3-[Phospho-L-Serine]:Cholesterol liposomes (DOPS-rSLPI) protects rSLPI against Cat L inactivation in vitro. We aimed to determine the effect of liposomes on rSLPI pharmacokinetics and activity in vitro and after local delivery to the airways in vivo.",

author = "A. Gibbons and D. Padilla-Carlin and C. Kelly and A.J. Hickey and Clifford Taggart and N.G. McElvaney and S.A. Cryan",

year = "2011",

month = sep,

doi = "10.1007/s11095-011-0454-1",

language = "English",

volume = "28 (9)",

pages = "2233--2245",

journal = "Pharmaceutical Research",

issn = "0724-8741",

publisher = "Springer",

number = "9",

}

Gibbons, A, Padilla-Carlin, D, Kelly, C, Hickey, AJ, Taggart, C, McElvaney, NG & Cryan, SA 2011, 'The Effect of Liposome Encapsulation on the Pharmacokinetics of Recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) Therapy after Local Delivery to a Guinea Pig Asthma Model', Pharmaceutical Research, vol. 28 (9), no. 9, pp. 2233-2245. https://doi.org/10.1007/s11095-011-0454-1

The Effect of Liposome Encapsulation on the Pharmacokinetics of Recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) Therapy after Local Delivery to a Guinea Pig Asthma Model. / Gibbons, A.; Padilla-Carlin, D.; Kelly, C. et al.
In: Pharmaceutical Research, Vol. 28 (9), No. 9, 09.2011, p. 2233-2245.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The Effect of Liposome Encapsulation on the Pharmacokinetics of Recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) Therapy after Local Delivery to a Guinea Pig Asthma Model

AU - Gibbons, A.

AU - Padilla-Carlin, D.

AU - Kelly, C.

AU - Hickey, A.J.

AU - Taggart, Clifford

AU - McElvaney, N.G.

AU - Cryan, S.A.

PY - 2011/9

Y1 - 2011/9

N2 - Inhaled recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) has shown potential for treatment of inflammatory lung conditions. Rapid inactivation of rSLPI by cathepsin L (Cat L) and rapid clearance from the lungs have limited clinical efficacy. Encapsulation of rSLPI within 1,2-Dioleoyl-sn-Glycero-3-[Phospho-L-Serine]:Cholesterol liposomes (DOPS-rSLPI) protects rSLPI against Cat L inactivation in vitro. We aimed to determine the effect of liposomes on rSLPI pharmacokinetics and activity in vitro and after local delivery to the airways in vivo.

AB - Inhaled recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) has shown potential for treatment of inflammatory lung conditions. Rapid inactivation of rSLPI by cathepsin L (Cat L) and rapid clearance from the lungs have limited clinical efficacy. Encapsulation of rSLPI within 1,2-Dioleoyl-sn-Glycero-3-[Phospho-L-Serine]:Cholesterol liposomes (DOPS-rSLPI) protects rSLPI against Cat L inactivation in vitro. We aimed to determine the effect of liposomes on rSLPI pharmacokinetics and activity in vitro and after local delivery to the airways in vivo.

U2 - 10.1007/s11095-011-0454-1

DO - 10.1007/s11095-011-0454-1

M3 - Article

SN - 0724-8741

VL - 28 (9)

SP - 2233

EP - 2245

JO - Pharmaceutical Research

JF - Pharmaceutical Research

IS - 9

ER -

The Effect of Liposome Encapsulation on the Pharmacokinetics of Recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) Therapy after Local Delivery to a Guinea Pig Asthma Model

Abstract

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this